Immunotherapy of cancer with pressure modified cells

Israel Medical Association Journal

Volumn 2, Issue 8, 2000, Pages 615-620

  Shinitzky, M ^a   Goldman, Y ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Adenosine diAldehyde; Hydrostatic pressure; Immunotherapy; Lung metastasis; N acetyl L cysteine

Indexed keywords

ACETYLCYSTEINE; ACTIN; CANCER VACCINE; HEAT SHOCK PROTEIN;

ANTIGEN PRESENTING CELL; CANCER; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; CROSS LINKING; HUMAN; IMMUNOGENICITY; LUNG METASTASIS; NONHUMAN; REVIEW; T LYMPHOCYTE RECEPTOR GENE; TUMOR IMMUNOLOGY; TUMOR MODEL; VACCINE PRODUCTION;

ANIMALS; ANTIGEN PRESENTATION; HEAT-SHOCK PROTEINS; HUMANS; HYDROSTATIC PRESSURE; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0033843641     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
2. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story
3. Tumor immunology: The glass is half full
4. Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies
5. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
6. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes
7. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
8. Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world
9. The labyrinthine ways of cancer immunotherapy - T cell, tumor cell encounter: 'How do I lose thee? Let me count the ways'
10. Potentiation of delayed-type hypersensitivity response to syngeneic tumors in mice prevaccinated with cells modified by hydrostatic pressure and crosslinking
11. Induction of cell-mediated immunity against B16-BL6 melanoma in mice vaccinated with cells modified by hydrostatic pressure and chemical crosslinking
12. Increased projection of MHC and tumor antigens in murine B16-BL6 melanoma induced by hydrostatic pressure and chemical crosslinking
13. Surface projection of murine major histocompatibility determinants induced by hydrostatic pressure and cytokines
14. Human tumor cells, modified by a novel pressure/crosslinking methodology, promote autologous lymphocyte proliferation and modulate cytokine secretion
15. Pressure-induced depolymerization of spindle microtubules. I: Changes in birefringence and spindle length
16. Shedding and isolation of the delta 6-desaturase system from rat liver microsomes by application of high hydrostatic pressure
17. Physiological levels of hydrostatic pressure alter morphology and organization of cytoskeletal and adhesion proteins in MG-63 osteosarcoma cells
18. Stress response of Escherichia coli to elevated hydrostatic pressure
19. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96
20. Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs
21. Thiols and the immune system: Effect of N-acetylcysteine on T cell system in human subjects
22. The immunological synapse: A molecular machine controlling T cell activation
23. From TCR engagement to T cell activation: A kinetic view of T cell behavior
24. Ligand recognition by alpha beta T cell receptors
25. Kinetic proofreading in T-cell receptor signal transduction
26. Effective elimination of lung metastases induced by tumor cells treated with hydrostatic pressure and N-acetyl-L-cysteine
27. An innate sense of danger
28. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function
29. Dendritic cells and the control of immunity
30. + T-helper and a T-killer cell
31. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein
32. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes
33. Active immunotherapy with allogeneic tumor cell vaccines: Present status
34. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells
35. Active specific immunotherapy for metastatic colorectal carcinoma: Phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha
36. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma
37. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma
38. Immunotherapy of acute lymphoblastic leukemia by vaccination with autologous leukemic cells transfected with a cDNA expression plasmid coding for an allogeneic HLA class I antigen combined with interleukin-2 treatment
39. A radioisotopic method to measure delayed type hypersensitivity in the mouse. I: Studies in sensitized and normal mice